세계의 원내감염 대책 시장 보고서(2025년)
Hospital-Acquired Infection Control Global Market Report 2025
상품코드 : 1824534
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,493,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,386,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,279,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

원내감염 대책 시장 규모는 향후 몇 년 동안 강력한 성장이 예상됩니다. 2029년 연평균 성장률(CAGR) 5.4%로 440억 6,000만 달러에 달할 것으로 예상됩니다. 예측 기간의 성장은 다제내성 병원체의 증가, 팬데믹 대비, 감시 및 모니터링 강화, 항균제 스튜어드십 프로그램, 국제 협력에 기인하는 것으로 보입니다. 예측 기간의 주요 동향으로는 실시간 위치추적 시스템(RTLS) 채택, 감시를 위한 인공지능(AI) 통합, 일회용 장비로의 전환, 직원 교육 및 훈련에 대한 중요성, 소독 기술 사용 증가 등이 있습니다.

향후 5년간 성장률 5.4%라는 예측은 지난번 예측보다 0.1% 소폭 하락한 수치입니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향에 기인합니다. 관세 부과는 네덜란드와 한국에서 수입되는 첨단 자외선 소독 시스템 및 항균 코팅제에 대한 접근을 제한하고, 감염 예방을 저해하고 중환자실 재입원율을 상승시킬 수 있기 때문에 미국에 큰 도전이 될 수 있습니다. 또한, 상호 관세와 무역 긴장과 제한의 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향은 더욱 광범위하게 나타날 것으로 보입니다.

원내감염 대책 시장은 COVID-19 확진자 급증으로 인해 성장의 원동력이 될 것으로 예상됩니다. SARS-CoV-2 바이러스로 인한 COVID-19는 개인 위생 및 의료용품 생산에 대한 중요성을 강조하며 감염 제어 제품 및 서비스에 대한 수요 증가로 이어지고 있습니다. 세계보건기구(WHO)에 따르면, 2022년 8월 8일 기준 전 세계 COVID-19 감염자 수는 5억 8,160만 명에 달해 팬데믹 진행에 따른 시장 확대를 뒷받침하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 전략

제36장 부록

KSM
영문 목차

영문목차

Hospital-acquired infections, acquired during hospital care and absent before admission, are managed through hospital-acquired infection control, employing cleaning, sterilization, and disinfection methods to reduce or eliminate transmission. These infections may stem from cross-contamination involving equipment surfaces, patient skin, and healthcare staff. The goal of hospital-acquired infection control is to curb the spread of illnesses.

The primary types of products in hospital-acquired infection control encompass sterilizers, disinfectors, endoscope reprocessors, microbial testing instruments, reagents, consumables, disinfectants, infection prevention and surveillance software, and others. Sterilizers, machines designed to thoroughly cleanse and eliminate bacteria, are employed to kill germs on surfaces or in fluids, preventing disease transmission. Various technologies, including phenotypic and genotypic methods, address diseases such as hospital-acquired pneumonia, bloodstream infections, surgical site infections, gastrointestinal infections, urinary tract infections, and others. Applications range from disease testing to drug-resistance testing, with end users including hospitals, ICUs, ambulatory surgical and diagnostic centers, nursing homes, maternity centers, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The hospital-acquired infection control market research report is one of a series of new reports from The Business Research Company that provides hospital-acquired infection control market statistics, including hospital-acquired infection control industry global market size, regional shares, competitors with a hospital-acquired infection control market share, detailed hospital-acquired infection control market segments, market trends and opportunities, and any further data you may need to thrive in the hospital-acquired infection control industry. This hospital-acquired infection control market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hospital-acquired infection control market size has grown steadily in recent years. It will grow from $34.59 billion in 2024 to $35.75 billion in 2025 at a compound annual growth rate (CAGR) of 3.4%. The growth in the historic period can be attributed to increasing antibiotic resistance, growing awareness, stringent regulations, globalization of infectious diseases, patient safety initiatives.

The hospital-acquired infection control market size is expected to see strong growth in the next few years. It will grow to $44.06 billion in 2029 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to rise of multidrug-resistant pathogens, pandemic preparedness, increased surveillance and monitoring, antimicrobial stewardship programs, international collaboration. Major trends in the forecast period include adoption of real-time location systems (RTLS), integration of artificial intelligence (AI) for surveillance, shift towards single-use and disposable devices, emphasis on staff training and education, increased utilization of disinfection technologies.

The forecast of 5.4% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may pose a significant challenge for the U.S. by restricting access to advanced UV disinfection systems and antimicrobial coatings imported from the Netherlands and South Korea, potentially compromising infection prevention and increasing ICU readmission rates. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The hospital-acquired infection control market is anticipated to experience growth driven by the surge in COVID-19 cases. COVID-19, caused by the SARS-CoV-2 virus, has led to an increased demand for infection control products and services, emphasizing personal hygiene and the production of medical supplies. As of August 8, 2022, global COVID-19 cases reached 581.6 million, according to the World Health Organization, underscoring the market's expansion due to the ongoing pandemic.

Rising healthcare expenditures are expected to drive the growth of the hospital-acquired infection control market. Healthcare expenditures encompass the total spending on healthcare services, products, and activities within a defined timeframe, whether at the individual, community, national, or global level. As healthcare spending increases, hospitals and healthcare facilities are likely to allocate more resources toward adopting advanced infection prevention technologies. This includes innovative solutions such as advanced disinfection systems, smart monitoring devices, and other technologies that enhance overall infection control measures. For example, in May 2024, the Office for National Statistics, a UK-based government agency, reported a 5.6% increase in total healthcare expenditure in nominal terms between 2022 and 2023, compared to a mere 0.9% growth in 2022. Consequently, the rising healthcare expenditure is poised to fuel the growth of the hospital-acquired infection control market in the future.

Leading companies in the hospital-acquired infection control market are concentrating on creating new technological solutions, such as AI systems aimed at the early identification of sepsis to improve patient outcomes through prompt diagnosis and treatment. An AI system designed to assist in recognizing sepsis refers to advanced technological solutions that employ artificial intelligence and machine learning algorithms to detect initial signs of sepsis in patients. For example, in April 2024, Prenosis Inc., a US-based medical clinic, obtained FDA marketing authorization for the Sepsis ImmunoScore, the first AI-driven system created to predict sepsis, a potentially life-threatening condition that can result in serious complications. This innovative tool enhances early detection by analyzing real-time data, enabling healthcare professionals to respond more quickly and effectively. The integration of AI is intended to support medical staff in their decision-making processes rather than replace them, ultimately leading to improved patient outcomes and reduced healthcare costs.

Major companies in the hospital-acquired infection control market are obtaining regulatory approvals to launch innovative products and technologies aimed at decreasing the incidence of infections within healthcare environments. Regulatory approvals refer to the authorizations granted by government agencies or regulatory bodies that permit a company to market and sell its products or services. For example, in May 2023, Innoviva Specialty Therapeutics, a US-based biopharmaceutical company, received approval for the new treatment Xacduro (sulbactam and durlobactam), which is designed for hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by specific strains of the Acinetobacter baumannii-calcoaceticus complex. This approval addresses the growing problem of antimicrobial resistance, particularly concerning Acinetobacter species. Xacduro combines sulbactam, which is effective against A. Common side effects may include abnormalities in liver function tests. The drug was granted several designations to expedite its development and review, underscoring its importance in treating severe bacterial infections in healthcare settings.

In August 2024, MicroCare, LLC, a US-based company that develops and manufactures cleaning and disinfecting products for the medical sector, acquired ICT Infection Control Technologies for an undisclosed amount. This acquisition allows MicroCare to enhance its healthcare portfolio by integrating ICT's specialized infection control solutions into its existing range of cleaning and lubrication products. This strategic move aims to strengthen MicroCare's position in the rapidly expanding medical infection prevention market, thereby improving the safety and effectiveness of cleaning solutions for healthcare facilities. ICT Infection Control Technologies is a US-based company that focuses on manufacturing infection control chemistries primarily for the dental and medical sectors.

Major companies operating in the hospital-acquired infection control market include Johnson and Johnson, P&G Professional, Honeywell International Inc., MMM Group, 3M Company, Becton Dickinson and Company, Reckitt Benckiser Group plc., Ecolab Inc, Olympus Corporation, Miele Group, Biomerieux SA, Getinge AB, Halyard Health Inc., Ansell Limited, Sotera Health LLC, Contec Inc., Cantel Medical Corp., Belimed AG, Nanosonics Limited, Advanced Sterilization Products Services Inc, Steelco S.P.A, Schulke & Mayr GmbH, Metrex Research LLC, Tristel Solutions Ltd., Whiteley Corporation, PDI Inc., Steris Healthcare PVT Ltd, Matachana Group, Pal International Ltd., Xttrium Laboratories Inc., Zep Inc.

North America was the largest region in the hospital-acquired infection control market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hospital-acquired infection control market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the hospital-acquired infection control market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hospital-acquired infection control market includes revenues earned by entities by heat sterilization equipment, low temperature sterilization equipment, radiation sterilization equipment, other sterilization equipment, contract sterilization services, sterilization consumables and accessories, disinfectants, and disinfectors equipment. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hospital-Acquired Infection Control Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hospital-acquired infection control market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for hospital-acquired infection control ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The hospital-acquired infection control market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Hospital-Acquired Infection Control Market Characteristics

3. Hospital-Acquired Infection Control Market Trends And Strategies

4. Hospital-Acquired Infection Control Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Hospital-Acquired Infection Control Growth Analysis And Strategic Analysis Framework

6. Hospital-Acquired Infection Control Market Segmentation

7. Hospital-Acquired Infection Control Market Regional And Country Analysis

8. Asia-Pacific Hospital-Acquired Infection Control Market

9. China Hospital-Acquired Infection Control Market

10. India Hospital-Acquired Infection Control Market

11. Japan Hospital-Acquired Infection Control Market

12. Australia Hospital-Acquired Infection Control Market

13. Indonesia Hospital-Acquired Infection Control Market

14. South Korea Hospital-Acquired Infection Control Market

15. Western Europe Hospital-Acquired Infection Control Market

16. UK Hospital-Acquired Infection Control Market

17. Germany Hospital-Acquired Infection Control Market

18. France Hospital-Acquired Infection Control Market

19. Italy Hospital-Acquired Infection Control Market

20. Spain Hospital-Acquired Infection Control Market

21. Eastern Europe Hospital-Acquired Infection Control Market

22. Russia Hospital-Acquired Infection Control Market

23. North America Hospital-Acquired Infection Control Market

24. USA Hospital-Acquired Infection Control Market

25. Canada Hospital-Acquired Infection Control Market

26. South America Hospital-Acquired Infection Control Market

27. Brazil Hospital-Acquired Infection Control Market

28. Middle East Hospital-Acquired Infection Control Market

29. Africa Hospital-Acquired Infection Control Market

30. Hospital-Acquired Infection Control Market Competitive Landscape And Company Profiles

31. Hospital-Acquired Infection Control Market Other Major And Innovative Companies

32. Global Hospital-Acquired Infection Control Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hospital-Acquired Infection Control Market

34. Recent Developments In The Hospital-Acquired Infection Control Market

35. Hospital-Acquired Infection Control Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기